DelMar Pharmaceuticals, Inc. (DMPI)

Oncology Corporate Profile

Stock Performance

2.0700
-0.0300

HQ Location

999 West Broadway
Vancouver, British Columbia V5Z 1K5

Company Description

DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme, the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

Website: http://www.delmarpharma.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
VAL-083bi-functional alkylating agentRefractory Glioblastoma Multiforme (GBM)III
VAL-083bi-functional alkylating agentFrontline Glioblastoma Multiforme (GBM)I
VAL-083bi-functional alkylating agentNon Small Cell Lung Cancer (NSCLC)Preclinical
VAL-083bi-functional alkylating agentOvarian cancerPreclinical

View additional information on product candidates here »

Source: http://www.delmarpharma.com

Recent News Headlines

7/27/2017 12:18 pm

7/27/2017 12:18 pm

7/27/2017 12:18 pm

7/27/2017 12:18 pm

7/27/2017 12:18 pm

7/24/2017 06:18 am

7/24/2017 06:18 am

7/24/2017 06:18 am

7/24/2017 06:18 am

7/24/2017 06:18 am

7/18/2017 06:18 am

7/18/2017 06:18 am

7/18/2017 06:18 am

7/18/2017 06:18 am

7/18/2017 06:18 am

7/11/2017 06:18 am

7/11/2017 06:18 am

7/11/2017 06:18 am

7/11/2017 06:18 am

7/11/2017 06:18 am

6/29/2017 06:18 am

6/22/2017 06:18 am

6/16/2017 06:18 am

5/18/2017 12:17 pm

5/11/2017 06:17 am